Site Map
Pages
- 5xFAD transgenic mouse model of AD
- Ab 1-42 -induced electrophysiological changes in hippocampal cultures.
- Ab1-42-induced apoptosis in PC12 cells.
- About us
- Acute rodent toxicity and genotoxicity screening
- Analysis of formulations
- Aβ injection model of AD
- Bacterial genotoxicity – SOS/umu
- Bacterial mutagenicity – Ames test
- BCRP Inhibition assay (Caco-2 cells)
- Bioanalytical Method Validation
- Brain Tissue Binding assay
- CHEMISTRY
- Clinical studies
- Computer Aided Drug Design
- Computer Aided Drug Design and Knowledge Management
- Contact
- Cookies Policy
- Cytochrome P450 (CYP) induction assay
- Cytochrome P450 (CYP) inhibition assay (IC50)
- Cytochrome P450 time dependent inhibition: IC50 shift assay
- DMPK and Bioanalysis
- Drug Discovery Workflow
- Drug-induced amnesia
- Efflux Transporter Substrate Identification assay (Caco-2 cells)
- Gastrointestinal permeability (GIT-PAMPA) and skin permeability (skin-PAMPA)
- Glutamate excitotoxicity
- Home
- Identification of EST64454
- Impurity identification
- In vitro cytotoxicity – MTT & NR
- In vitro mitochondrial toxicity
- In vitro Pharmacology
- In vitro phospholipidosis
- In vivo Pharmacology
- Irwin`s test in rodent
- Legal Notice
- Lipophilicity determination
- Mammalian cell genotoxicity – Micronucleus test
- Metabolic stability assay in hepatocytes
- Metabolic stability assay in liver microsomes
- Metabolite identification
- Metabolite Profiling & Identification in vitro / in vivo
- Method development and validation
- MPP+ neurotoxicity in SH-SY5Y cells
- Multimodal Therapy
- Multiparametric optimization
- Neuropathic pain
- Neuropathic painChemotherapy-induced peripheral neuropathy (CIPN)
- Neuropathic painSpared nerve injury (SNI) induced neuropathy
- News
- News
- Nociplastic pain
- Osteoarthritis pain MIA-induced articular pain
- P-gp Inhibition assay (Caco-2 cells)
- Partnership
- Permeability assay (Caco-2 cells)
- Pharmacokinetic assay in mice
- Pharmacokinetic assay in rats
- Pharmacokinetics in rodents
- Pharmacokinetics in non-rodents
- Physicochemical characterization
- Plasma Protein Binding assay
- Plasma stability
- Preparative separation and purification
- Privacy Policy
- Protein Binding assay
- Red blood cell binding
- Renal excretion
- Repeated dose toxicity in rodent
- Repeated scopolamine model of AD
- Site Map
- Solid form selection
- Solubility determination
- Stability and forced degradation
- Structural elucidation and characterization
- Tissue Kinetics
- Toxicokinetics
- Toxicology
- Tunicamycin-induced mitochondrial ATP in NSC-34 cells
- Welabrary
- WLB-73502 Dual m-opioid/s1 receptor ligand
Posts by category
- Category: News
- XV SDDN meeting 2023, Barcelona
- A new JMedChem publication from Welab
- Fundación MEDINA and WeLab Barcelona
- New Sigma-1 receptor-BiP biosensor
- Taros – Welab collaboration agreement
- Pharmacelera-Welab partnership agreement
- Where does our logo come from?
- Spirify – Welab Barcelona research collaboration
- Carcinogenicity studies of cizolirtine, a substance-P and calcitonin gene-related peptide release modulator
- Comprehensive Preclinical Assessment of Sensory, Functional, Motivational-Affective, and Neurochemical Outcomes in Neuropathic Pain
- Pharmacological Probes to Validate Biomarkers for Analgesic Drug Development
- New publication in ACS Medicinal Chemistry Letters
- IMI-Paincare General Assembly
- Welab is GLP certified R&D site
- Welab has signed an Agreement with the consortium IMI-Paincare, through the partner Consultech GmbH
- ESTEVE and LEITAT announce strategic partnership to collaborate in research and development
Welab Barcelona is a Spanish leading platform for Drug Discovery and Development. Our goal is to be your partner in creating the next generation of tomorrow’s medicines
Contact
- Parc Científic de Barcelona, Edifici Clúster II, Planta 4, Baldiri Reixac, 4-8. 08028 Barcelona Spain
Information
© 2023 Welab Barcelona. All Rights Reserved. Web design: Turipano360